Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage

Andrew P. Carlson, Daniel Hänggi, George K. Wong, Nima Etminan, Stephan A. Mayer, François Aldrich, Michael N. Diringer, Erich Schmutzhard, Herbert J. Faleck, David Ng, Benjamin R. Saville, Thomas Bleck, Robert Grubb, Michael Miller, Jose I. Suarez, Howard M. Proskin, R. Loch MacDonald, Amal Abou-Hamden, Rodney Allan, Laith AltaweelArun Amar, Sepideh Amin-Hanjani, Khaled Aziz, Nicholas Bambakidis, Michel Bojanowski, Ondrej Bradac, Sherry Chou, Wayne Marston Clark, Tim Darsaut, Koji C. Ebersole, Lucas Elijovich, William D. Freeman, Roland Goldbrunner, Carmelo Graffagnino, Gaurav Gupta, Jirina Habalova, Moshe Hadani, Sagi Harnof, Mark Robert Harrigan, Kevin Hatton, Raimund Helbok, Tomas Hrbac, Hagen B. Huttner, Pascal Jabbour, Babak Jahromi, Robert James, Joseph Dedrick Jordan, Michael Kelly, Riku P. Kivisaari, Nerissa Ko, Jürgen Konczalla, David Kung, Shouri Lahiri, David Langer, Matthew Lawson, Cappi Lay, David Ledoux, George A. Lopez, Wai Man Lui, Charles Matouk, Edward W. Mee, Jürgen Meixensberger, Oliver Müller, Vincent Ng Yew Poh, Juha Öhman, Peter Papadakos, Aman B. Patel, Adam Polifka, Wai Sang Poon, Ciaran Powers, John Reavey-Cantwell, Gary Redekop, Jan Regelsberger, Guy Rosenthal, Yu Mi Ryang, Eric Sauvageau, Ian Seppelt, Martin Smrcka, Julian Spears, Ajith Thomas, Raymond Turner, Andreas Unterberg, Peter Vajkoczy, Paul Vespa, Daniel E. Walzman, Thomas Westermaier, John Wong, Menashe Zaaroor, Joseph Zabramski

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Background and Purpose - EG-1962 is a sustained release formulation of nimodipine administered via external ventricular drain in patients with aneurysmal subarachnoid hemorrhage. A randomized, open-label, phase 1/2a, dose-escalation study provided impetus for this study to evaluate efficacy and safety of a single intraventricular 600 mg dose of EG-1962 to patients with aneurysmal subarachnoid hemorrhage, compared with standard of care oral nimodipine. Methods - Subjects were World Federation of Neurological Surgeons grades 2-4, modified Fisher grades 2-4 and had an external ventricular drain inserted as part of standard of care. The primary end point was the proportion of subjects with favorable outcome at day 90 after aneurysmal subarachnoid hemorrhage (extended Glasgow outcome scale 6-8). The proportion of subjects with favorable outcome at day 90 on the Montreal cognitive assessment, as well as the incidence of delayed cerebral ischemia and infarction, use of rescue therapy and safety were evaluated. Results - The study was halted by the independent data monitoring board after planned interim analysis of 210 subjects (289 randomized) with day 90 outcome found the study was unlikely to achieve its primary end point. After day 90 follow-up of all subjects, the proportion with favorable outcome on the extended Glasgow outcome scale was 45% (65/144) in the EG-1962 and 42% (62/145) in the placebo group (risk ratio, 1.01 [95% CI, 0.83-1.22], P=0.95). Consistent with its mechanism of action, EG-1962 significantly reduced vasospasm (50% [69/138] EG-1962 versus 63% [91/144], P=0.025) and hypotension (7% [9/138] versus 10% [14/144]). Analysis of prespecified subject strata suggested potential efficacy in World Federation of Neurological Surgeons 3-4 subjects (46% [32/69] EG-1962 versus 32% [24/75] placebo, odds ratio, 1.22 [95% CI, 0.94-1.58], P=0.13). No safety concerns were identified that halted the study or that preclude further development. Conclusions - There was no significant increase in favorable outcome for EG-1962 compared with standard of care in the overall study population. The safety profile was acceptable.

Original languageEnglish
Pages (from-to)1142-1149
Number of pages8
Issue number4
StatePublished - Apr 1 2020


  • clinical trial
  • infarction
  • nimodipine
  • standard of care
  • subarachnoid hemorrhage


Dive into the research topics of 'Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage'. Together they form a unique fingerprint.

Cite this